Company News
Company News
Core One Labs’ Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential
September 16, 2022
Vancouver, British Columbia, Canada – September 16, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One Labs’ Scientists Successfully Complete Breakthrough First Step in Producing API-Grade DMT
September 02, 2022
Second Ground Breaking Technological Advancement
Vancouver, British Columbia, Canada – September 2, 2022 – Core One Labs Inc. (CSE: COOL),...
Read more
Company News
Core One Rolls Out Commercial Sales Strategy for its Revolutionary API Grade Biosynthetic Psilocybin
September 01, 2022
Vancouver, British Columbia, Canada – September 1 2022 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One Labs Applauds New Study Supporting Psilocybin Psychedelic Drug Therapy May Help Treat Alcohol Addiction
August 30, 2022
Vancouver, British Columbia, Canada - August 30, 2022 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (FWB: LD6,...
Read more
Company News
Core One Labs Engages in Talks with GMP Manufacturing Partner for Commercial Scale Production of Proprietary Biosynthetic Psilocybin
August 26, 2022
Vancouver, British Columbia, Canada – August 26, 2022 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”...
Read more
Company News
Core One Labs’ Akome Achieves Another Milestone in Development of its Psychedelic Drug Formulas and Announces Positive Results from Neuro-Pharmacokinetics Studies
August 19, 2022
Vancouver, British Columbia, Canada – August 19, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more